Mesoblast (NASDAQ: MESO) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.
This is a summary of recent ratings and recommmendations for Mesoblast and AC Immune, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Mesoblast has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500.
Institutional & Insider Ownership
3.0% of Mesoblast shares are held by institutional investors. Comparatively, 19.6% of AC Immune shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Mesoblast and AC Immune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Mesoblast and AC Immune’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mesoblast||$2.41 million||260.63||-$76.81 million||($0.37)||-18.03|
|AC Immune||$23.55 million||28.86||-$7.20 million||N/A||N/A|
AC Immune has higher revenue and earnings than Mesoblast.
AC Immune beats Mesoblast on 8 of the 12 factors compared between the two stocks.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
About AC Immune
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.